extension

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis demonstrated the earliest known time to separation in…

3 days ago

Algernon Announces Warrant Extension

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov.…

2 weeks ago